Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: A potential diagnostic and treatment biomarker

Biochemical and Biophysical Research Communications

Volumn 434, Issue 2, 2013, Pages 293-297

  Görtz, Philipp ^a   Siebler, Mario ^a,b   Ihl, Ralf ^a,c   Henning, Uwe ^a   Luckhaus, Christian ^a   Supprian, Tillmann ^a   Lange Asschenfeldt, Christian ^a  

^a Department of Orthopedic Surgery   (Germany)

^b MediClin Rhein Ruhr ^*  (Germany)

^c Krankenhaus Maria Hilf   (Germany)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Mild cognitive impairment; Multielectrode array; Neuronal network activity

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BIOASSAY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ELECTRIC ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR DIAGNOSIS; MULTIELECTRODE ARRAY NEUROCHIP; NERVE CELL CULTURE; NERVE CELL NETWORK; NERVE FIBER GROWTH; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PSYCHOMETRY; RAT; SCREENING TEST;

AGED; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CEREBROSPINAL FLUID; COGNITION; CULTURE MEDIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NERVE NET; NEURITES; NEURONS; PILOT PROJECTS; PROTEIN ARRAY ANALYSIS; RATS;

EID: 84877083442     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.121     Document Type: Article

References (24)

1. Tumani H., Brettschneider J. Biochemical markers of autoimmune diseases of the nervous system. Curr. Pharm. Des. 2012, 18:4556-4563.
2. Tarasiuk J., Kulakowska A., Drozdowski W., Kornhuber J., Lewczuk P. CSF markers in amyotrophic lateral sclerosis. J. Neural Transm. 2012, 119:747-757.
3. Stefani A., Brusa L., Olivola E., Pierantozzi M., Martorana A. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J. Neural Transm. 2012, 119:861-875.
4. Otto F., Illes S., Opatz J., Laryea M., Theiss S., Hartung H.P., Schnitzler A., Siebler M., Dihne M. Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann. Neurol. 2009, 66:546-555.
5. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45:545-552.
6. Dubois B., Feldman H.H., Jacova C., Cummings J.L., DeKosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
7. Gauthier S., Dubois B., Feldman H., Scheltens P. Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurol. 2008, 7:668-670.
8. Marksteiner J., Pirchl M., Ullrich C., Oberbauer H., Blasko I., Lederer W., Hinterhuber H., Humpel C. Analysis of cerebrospinal fluid of Alzheimer patients, Biomarkers and toxic properties. Pharmacology 2008, 82:214-220.
9. Hampel H., Shen Y., Walsh D.M., Aisen P., Shaw L.M., Zetterberg H., Trojanowski J.Q., Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp. Neurol. 2010, 223:334-346.
10. Johnstone A.F., Gross G.W., Weiss D.G., Schroeder O.H., Gramowski A., Shafer T.J. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. Neurotoxicology 2010, 31:331-350.
11. Görtz P., Opatz J., Siebler M., Funke S.A., Willbold D., Lange-Asschenfeldt C. Transient reduction of spontaneous neuronal network activity by sublethal amyloid beta (1-42) peptide concentrations. J. Neural Transm. 2009, 116:351-355.
12. Görtz P., Hoinkes A., Fleischer W., Otto F., Schwahn B., Wendel U., Siebler M. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J. Neurol. Sci. 2004, 218:109-114.
13. Görtz P., Koller H., Schwahn B., Wendel U., Siebler M. Disturbance of cultured rat neuronal network activity depends on concentration and ratio of leucine and alpha-ketoisocaproate: implication for acute encephalopathy of maple syrup urine disease. Pediatr. Res. 2003, 53:320-324.
14. Gramowski A., Jugelt K., Stuwe S., Schulze R., McGregor G.P., Wartenberg-Demand A., Loock J., Schröder O., Weiss D.G. Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. Eur. J. Neurosci. 2006, 24:455-465.
15. Xia Y., Gopal K.V., Gross G.W. Differential acute effects of fluoxetine on frontal and auditory cortex networks in vitro. Brain Res. 2003, 973:151-160.
16. Xiang G., Pan L., Huang L., Yu Z., Song X., Cheng J., Xing W., Zhou Y. Microelectrode array-based system for neuropharmacological applications with cortical neurons cultured in vitro. Biosens. Bioelectron. 2007, 22:2478-2484.
17. Xia Y., Gross G.W. Histiotypic electrophysiological responses of cultured neuronal networks to ethanol. Alcohol 2003, 30:167-174.
18. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
19. Otto F., Görtz P., Fleischer W., Siebler M. Cryopreserved rat cortical cells develop functional neuronal networks on microelectrode arrays. J. Neurosci. Methods 2003, 128:173-181.
20. Mu X., Wu A., Wu J., Liu Y., Zhang Y., Yue Y., Fang L., Wang Y. Effects of anesthetic propofol on release of amino acids from the spinal cord during visceral pain. Neurosci. Lett. 2010, 484:206-209.
21. Antonova I., Arancio O., Trillat A.C., Wang H.G., Zablow L., Udo H., Kandel E.R., Hawkins R.D. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science 2001, 294:1547-1550.
22. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.
23. Wang-Dietrich L., Funke S.A., Kuhbach K., Wang K., Besmehn A., Willbold S., Cinar Y., Bannach O., Birkmann E., Willbold D. The Amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J. Alzheimers Dis. 2013, 34:985-994.
24. Santos A.N., Ewers M., Minthon L., Simm A., Silber R.E., Blennow K., Prvulovic D., Hansson O., Hampel H. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J. Alzheimers Dis. 2012, 29:171-176.